Kodiak Sciences : 2025 IOIS Kodiak Sciences
KOD
Published on 06/27/2025 at 06:08
THE OPHTHALMOLOGY MEDICINES COMPANY
A First-in-Class Investigational Bispecific Intravitreal Biologic for the Treatment of Macular Edema Secondary to Inflammation (MESI)
International Ocular Inflammation Society 2025
Kodiak Today
3
Victor Perlroth, MD
CEO, Kodiak Sciences
Three late-phase clinical assets
Advancing in parallel across a broad spectrum of retinal diseases in growing markets.
On track for phase 1b data in 2025 and Phase 3 topline
data in 2026
Dedicated commercial scale manufacturing facility
Custom designed, commercial scale manufacturing facility dedicated to the premium manufacture of Kodiak's ABC® medicines.
Commissioned as a cGMP facility in 2023
BLA filing preparation
On track towards our goal of filing a single BLA for tarcocimab in the 3 large indications of wet AMD, retinal vein occlusion and diabetic retinopathy in 2026.
BLA-facing data for KSI-501 and KSI-101 is
expected 2026
Visual engagement platform
Visual engagement technology and imager (VETi), an autonomous AI- and machine-learning-enabled headset that engages directly into the eye for retina disease management & longterm health engagement
Robust pipeline program
Kodiak's next set of investigational therapies targeting glaucoma and geographic atrophy, built on the ABC® platform, enabling an even larger group of high unmet need diseases and patients
4
Three clinical assets include tarcocimab (Phase 3), KSI-501 (Phase 3), and KSI-101 (Phase 1b; expected to initiate dual PEAK/PINNACLE Phase 3 studies mid 2025). ABC: antibody biopolymer conjugate; BLA: biologics license application; AMD: age-related macular degeneration
Kodiak is a precommercial, retina-focused biotech with a maturing
MOA
Inflammation
Anti-IL-6, anti-IL-1 Protein
Inflammation
Anti-IL-6, anti-TNF- Protein
Macular Edema Secondary to Inflammation (MESI)
Anti-IL-6, VEGF
Trap Protein
Wet AMD
Anti-IL-6, VEGF
Trap ABC
RVO
Wet AMD
Diabetic Retinopathy
Anti-VEGF Antibody Biopolymer Conjugate (ABC)
Tarcocimab
Phase 3
Phase 1/2
Pre-IND
Pre-clinical
Indication/MOA
KSI-102
KSI-103
KSI-101
KSI-501
GLOW1 primary endpoint met
GLOW2 topline data expected Q1 2026
DAYLIGHT primary endpoint met
DAYBREAK actively enrolling; topline data expected mid-2026
BEACON primary endpoint met
portfolio in retinal vascular disease and in ocular inflammation
5
DAYBREAK actively enrolling
Topline data expected mid-2026
Phase 1b APEX study ongoing
Emerging APEX data 2Q and 3Q 2025
On track to initiate Phase 3 PEAK and PINNACLE studies in 2Q 2025
Entering IND enabling studies
ABC: antibody biopolymer conjugate; RVO: retinal vein occlusion; AMD: age-related macular degeneration
Disclaimer
Kodiak Sciences Inc. published this content on June 27, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 27, 2025 at 10:07 UTC.